Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus gasseri is a probiotic bacterium that has been studied for its potential role in supporting inflammatory bowel disorders (IBD), such as Crohn’s disease and ulcerative colitis. While there is scientific interest in the use of probiotics for IBD, the specific evidence for L. gasseri is limited and somewhat preliminary. Some small-scale clinical studies and animal models have suggested that L. gasseri can modulate immune responses, enhance epithelial barrier function, and reduce inflammatory markers in the gut. For example, experimental models have shown that L. gasseri administration can decrease pro-inflammatory cytokines and improve intestinal histology. One randomized controlled trial reported that L. gasseri supplementation led to symptomatic improvement in patients with mild to moderate ulcerative colitis, but the sample size was small and results have not yet been widely replicated. Meta-analyses and systematic reviews addressing probiotics in IBD generally focus on mixed formulations or other Lactobacillus species, with only occasional inclusion of L. gasseri. Thus, while there is some scientific rationale and preliminary data supporting its use, the overall evidence base is modest and not yet definitive. Major gastroenterological guidelines do not specifically recommend L. gasseri as a first-line probiotic for IBD management. In summary, L. gasseri shows promise, but more robust and large-scale clinical trials are needed to establish its efficacy and safety in this context.

More about Lactobacillus gasseri
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Lactobacillus gasseri

Products containing Lactobacillus gasseri